38973-36-3

Upstream product

• 148318-12-1 3-amino-1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline 
• 26954-85-8 o-homoveratroylhomoveratric acid 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 40940-49-6 ethyl 2-<2'-<1''-(3,4-dimethoxyphenyl)-2''-oxoethyl>-4',5'-dimethoxyphenyl>acetic acid 
• 77287-34-4 formamide 
• 18066-68-7 ethyl 3,4-dimethoxyphenylacetate 
• 85155-40-4 1-(3',4'-dimethoxybenzyl)-6,7-dimethoxy-4-bromoisoquinolin-3-one 
• 172421-62-4 3-acetylamino-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline 

Downstream Products

• 377733-22-7 (3,4-dimethoxy-phenyl)-(3-hydroxy-6,7-dimethoxy-isoquinolin-1-yl)-methanone 
• 37415-52-4 6,7-dimethoxy-2-methyl-1-veratryl-3(2H)-isoquinolone hydrochloride 
• 85169-80-8 1-(3',4'-dimethoxybenzyl)-1,6,7-trimethoxyisoquinoline-3,4-dione 
• 68244-09-7 1-(3',4'-dimethoxybenzyl)-6,7-dimethoxy-4-nitroisoquinolin-3-one 
• 85155-40-4 1-(3',4'-dimethoxybenzyl)-6,7-dimethoxy-4-bromoisoquinolin-3-one 
• 68244-14-4 1-(E)-(3',4'-dimethoxybenzylidene)-6,7-dimethoxyisoquinoline-3,4-dione 
• 68244-10-0 1-(3',4'-dimethoxybenzyl)-6,7-dimethoxy-4-aminoisoquinolin-3-one 
• 68244-15-5 1-(Z)-(3',4'-dimethoxybenzylidene)-6,7-dimethoxyisoquinoline-3,4-dione 
• 42047-55-2 6,7-dimethoxy-1-veratryl-3-isoquinolinol silver salt 
• 42047-59-6 3-benzyloxy-1-(3,4-dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline 

Relevant academic research and scientific papers

Discovery of a series of nonpeptide small molecules that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins

Insulin-like growth factors (IGF-I and II) play an important role in metabolic and mitogenic activities through stimulation of the IGF-I receptor on the cell surface. Although the concentration of IGF in blood and cerebrospinal fluid is quite high (>100 nM) this large pool of IGF is biologically inactive because of its association with six distinct binding proteins which form high-affinity complexes with IGF. Thus, inhibitors of IGF-binding proteins (IGFBPs), especially IGFBP-3, could potentially alter the distribution between the "free" and "bound" forms of IGF and thereby elevate biologically active IGF-I to exert a beneficial effect on those patients with diseases that respond to the application of exogenous IGF-I. Whereas IGF-I peptide variants which bind to IGFBPs but not the IGF-I receptor have been shown to be potent IGF/IGFBP inhibitors small molecule nonpeptide IGF/IGFBP inhibitors have the potential advantages of oral bioavailability and flexible dosing regimen. Here we report the discovery of several isoquinoline analogues, exemplified by 1 and 2, which bind IGFBP-3 as well as other IGFBPs at low nanomolar concentrations. More importantly, both compounds were shown to be able to release biologically active IGF-I from the IGF-I/IGFBP-3 complex. These results point to the feasibility of developing orally active therapeutics to treat IGF-responsive diseases by optimization of the lead molecules 1 and 2.

Synthesis of 3-oxo-2,3-dihydroisoquinolines from ethyl 2-acylphenylacetates and formamides

1- and 1,3-substituted 3-oxo-2,3-dihydroisoquinolines 4 are obtained from ethyl 2-acylphenylacetates 3 and formamides.

Radical cyclization to aporphines. A new, efficient total synthesis of the aporphine glaucine and the 4,5-dioxoaporphine pontevedrine, and the first total synthesis of 5-oxoaporphines

We describe the radical cyclization of bromobenzylisoquinolines and benzylisoquinolin-3-ones, which afford aporphines or the novel 5-oxoaporphines and 5-oxodehydroaporphines respectively. Oxidation of the latter compounds provides a new route to 4,5-dioxoaporphines.

3(2H)-Isoquinolones therapeutic process

New 2-substituted-3(2H)-isoquinolones and 2-substituted-3-alkoxyisoquinolines are disclosed. They are orally active hypotensives and peripheral vasodilators with an extended duration of action. Representative embodiments of this invention are 6,7-dimethoxy-2-methyl-1-veratryl-3(2H)-isoquinolone hydrochloride, 2-allyl-6,7-dimethoxy-1-veratryl-3(2H)-isoquinolone hydrochloride, 2-cyclopropyl-6,7-dimethoxy-1-veratryl-3(2H)-isoquinolone hydrochloride, 2-amino-6,7-dimethoxy-1-veratryl-3(2H)-isoquinolone hydrochloride, and 3-ethoxy-6,7-dimethoxy-1-veratrylisoquinoline.